论文部分内容阅读
目的探讨氨氯地平/阿托伐他汀复方制剂对高血压合并动脉粥样硬化患者的影响。方法选择2011年1月—2014年1月就诊的87例患者,随机分为两组,对照组43例,口服氨氯地平5 mg,1次/d。观察组44例,口服氨氯地平/阿托伐他汀复方制剂,依据实际情况调整剂量。连续治疗6个月。比较两组治疗前后血压、内-中膜厚度(intima media thickness,IMT)、血管内皮功能以及氧化应激指标的变化水平。计量资料比较采用t检验。计数资料采用χ2检验,P<0.05为差异有统计学意义。结果治疗后观察组IMT水平明显低于对照组[(1.17±0.13)、(1.31±0.22)mm],对比差异有统计学意义(P<0.05)。治疗后,观察组丙二醛(malondialdehyde,MDA)、血管性血友病因子(von Willebrand factor,v WF)、内皮素-1(endothelin-1,ET-1)[(4.02±0.33)μmol/L、(149.7±19.8]%、(48.3±5.5)ng/L]明显低于对照组[(5.31±0.47)μmol/L、(172.6±22.1)%、(56.7±6.2)ng/L],超氧化物歧化酶(superoxide dismutase,SOD)、一氧化氮(nitric oxide,NO)[(113.5±8.7)U/ml、(81.2±11.2)μmol/L]明显高于对照组[(80.3±6.5)U/ml、(69.2±8.4)μmol/L],对比差异均有统计学意义(均P<0.05),无明显不良反应。结论氨氯地平/阿托伐他汀复方制剂治疗高血压,能有效地逆转氧化应激所致的损伤,降低氧化应激水平,改善血管内皮功能,延缓高血压的进展。
Objective To investigate the effect of amlodipine / atorvastatin on patients with hypertension and atherosclerosis. Methods 87 patients admitted from January 2011 to January 2014 were randomly divided into two groups. The control group received oral amlodipine 5 mg once daily. Observation group of 44 patients, oral amlodipine / atorvastatin compound preparation, according to the actual situation to adjust the dose. Continuous treatment for 6 months. The changes of blood pressure, intima media thickness (IMT), endothelial function and oxidative stress were compared between the two groups before and after treatment. Measurement data using t test. Count data using χ2 test, P <0.05 for the difference was statistically significant. Results After treatment, the IMT level in the observation group was significantly lower than that in the control group [(1.17 ± 0.13) and (1.31 ± 0.22) mm], respectively. The difference was statistically significant (P <0.05). After treatment, the malondialdehyde (MDA), von Willebrand factor (v WF) and endothelin-1 (ET-1) [(4.02 ± 0.33) μmol / L, (149.7 ± 19.8)% and (48.3 ± 5.5) ng / L, respectively, were significantly lower than those in the control group (5.31 ± 0.47 μmol / L, 172.6 ± 22.1% and 56.7 ± 6.2 ng / L, The superoxide dismutase (SOD), nitric oxide (NO) [(113.5 ± 8.7) U / ml, (81.2 ± 11.2) μmol / L] were significantly higher than those in the control group [(80.3 ± 6.5 ), U / ml, (69.2 ± 8.4) μmol / L], the difference was statistically significant (all P <0.05), no significant adverse reactions.Conclusion Amlodipine / atorvastatin compound preparation for the treatment of hypertension, Effectively reversing the damage caused by oxidative stress, reducing the level of oxidative stress, improving endothelial function and slowing the progression of hypertension.